{
  "id": "601c317a1cb411341a000014",
  "type": "factoid",
  "question": "Which molecule is targeted by Upadacitinib?",
  "ideal_answer": "Upadacitinib is a Janus kinase 1 inhibitor developed for treatment of moderate to severe rheumatoid arthritis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31287230",
    "http://www.ncbi.nlm.nih.gov/pubmed/31781755",
    "http://www.ncbi.nlm.nih.gov/pubmed/31867699",
    "http://www.ncbi.nlm.nih.gov/pubmed/29688617",
    "http://www.ncbi.nlm.nih.gov/pubmed/31130260",
    "http://www.ncbi.nlm.nih.gov/pubmed/30973649",
    "http://www.ncbi.nlm.nih.gov/pubmed/31654328",
    "http://www.ncbi.nlm.nih.gov/pubmed/31448433",
    "http://www.ncbi.nlm.nih.gov/pubmed/31692920",
    "http://www.ncbi.nlm.nih.gov/pubmed/31317509",
    "http://www.ncbi.nlm.nih.gov/pubmed/31378969",
    "http://www.ncbi.nlm.nih.gov/pubmed/32648334",
    "http://www.ncbi.nlm.nih.gov/pubmed/32776305",
    "http://www.ncbi.nlm.nih.gov/pubmed/32044319",
    "http://www.ncbi.nlm.nih.gov/pubmed/31786154",
    "http://www.ncbi.nlm.nih.gov/pubmed/28762476",
    "http://www.ncbi.nlm.nih.gov/pubmed/30633369",
    "http://www.ncbi.nlm.nih.gov/pubmed/29908670",
    "http://www.ncbi.nlm.nih.gov/pubmed/28503781",
    "http://www.ncbi.nlm.nih.gov/pubmed/31401212",
    "http://www.ncbi.nlm.nih.gov/pubmed/33129109",
    "http://www.ncbi.nlm.nih.gov/pubmed/30725185",
    "http://www.ncbi.nlm.nih.gov/pubmed/31327403",
    "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
    "http://www.ncbi.nlm.nih.gov/pubmed/29672874",
    "http://www.ncbi.nlm.nih.gov/pubmed/29908669",
    "http://www.ncbi.nlm.nih.gov/pubmed/29076110",
    "http://www.ncbi.nlm.nih.gov/pubmed/30886973",
    "http://www.ncbi.nlm.nih.gov/pubmed/28765121",
    "http://www.ncbi.nlm.nih.gov/pubmed/30500075",
    "http://www.ncbi.nlm.nih.gov/pubmed/32530345"
  ],
  "snippets": [
    {
      "text": "We summarise the development and recent application of Janus kinase (JAK) inhibitors in the treatment of IMIDs, including first-generation pan-JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib) and second-generation selective JAK inhibitors (decernotinib, filgotinib, upadacitinib).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765121",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib is a Janus kinase 1 inhibitor currently being evaluated in phase III rheumatoid arthritis trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28762476",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES: Upadacitinib is a janus kinase (JAK) 1 inhibitor being developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29076110",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: In randomised controlled trials primary efficacy endpoints were met for tofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM300 (\u03b14-integrin antagonist-phase II) in ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29672874",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib is a Janus kinase 1 inhibitor under development for the treatment of several inflammatory disorders including rheumatoid arthritis (RA). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688617",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib selectively inhibits Janus Kinase 1 (JAK1) which could potentially reduce JAK2 and JAK3-related side effects. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nPhase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29908670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nUpadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29908669",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib is a novel selective oral Janus kinase 1 (JAK) inhibitor being developed for treatment of several inflammatory diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30500075",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES\nUpadacitinib is a janus kinase (JAK) 1 inhibitor being developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29076110",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIMS\nUpadacitinib (ABT-494) is a selective Janus kinase 1 inhibitor being developed for treatment of auto-immune inflammatory disorders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28503781",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS\nIn randomised controlled trials primary efficacy endpoints were met for tofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM300 (\u03b14-integrin antagonist-phase II) in ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29672874",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIMS Upadacitinib (ABT-494) is a selective Janus kinase 1 inhibitor being developed for treatment of auto-immune inflammatory disorders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28503781",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29908669",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib selectively inhibits Janus Kinase 1 (JAK1) which could potentially reduce JAK2 and JAK3-related side effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert commentary: Upadacitinib has displayed a rapid and favorable efficacy profile in RA but despite being a selective JAK1 inhibitor appears to have a similar safety profile to less-selective Jakinibs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES Upadacitinib is a janus kinase (JAK) 1 inhibitor being developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29076110",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib is a Janus kinase 1 inhibitor under development for the treatment of several inflammatory disorders including rheumatoid arthritis (RA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688617",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: In this paper, we review a newly developed oral selective JAK inhibitor, upadacitinib for the treatment of RA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib selectively inhibits Janus Kinase 1 (JAK1) which could potentially reduce JAK2 and JAK3-related side effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>AIMS</b>: Upadacitinib (ABT-494) is a selective Janus kinase 1 inhibitor being developed for treatment of auto-immune inflammatory disorders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28503781",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert commentary: Upadacitinib has displayed a rapid and favorable efficacy profile in RA but despite being a selective JAK1 inhibitor appears to have a similar safety profile to less-selective Jakinibs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28503781",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Upadacitinib (ABT-494) is a selective Janus kinase 1 inhibitor being developed for treatment of auto-immune inflammatory disorders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28503781",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: In this paper, we review a newly developed oral selective JAK inhibitor, upadacitinib for the treatment of RA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES: We assessed the relative efficacy and safety of once-daily administration of 15 and 30\u202fmg upadacitinib (a\u00a0JAK1-selective inhibitor) in patients with active rheumatoid arthritis (RA)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30725185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In contrast, efficacy of filgotinib, a selective JAK1 inhibitor, in CD patients was demonstrated in the randomized, double-blinded, placebo-controlled phase II FITZROY study. Upadacitinib also showed promising results in a phase II trial in moderate to severe CD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31781755",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib is a Janus kinase\u00a01 inhibitor developed for treatment of moderate to severe rheumatoid arthritis (RA) and was recently approved by the US Food and Drug Administration for this indication in adults who have had an inadequate response or intolerance to methotrexate. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31867699",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BJECTIVE: We sought to evaluate the safety and efficacy of multiple doses of the selective Janus kinase 1 inhibitor upadacitinib in patients with moderate to severe atopic dermatitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31786154",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The aim of this study was to characterize the effects of upadacitinib, a Janus kinase 1 inhibitor, on in vivo activity of different cytochrome P450 (CYP) enzymes using a cocktail approach. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31378969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "thods: Structure-based hypotheses were used to design the JAK1 selective inhibitor upadacitinib. J",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30886973",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "S: In randomised controlled trials primary efficacy endpoints were met for tofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM300 (\u03b14-integrin antagonist-phase II) in ulcerative colitis. Ozani",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29672874",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Both these new compounds are active on the majority of four JAK family members (JAK1, JAK2, JAK3, and TYK2), whereas the most recent emerging approach is directed toward the development of JAK1 selective inhibitors (upadacitinib and filgotinib) with the aim to improve the safety profile by minimizing the effects on JAK3 and, especially, JAK2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692920",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib (ABT-494) is a selective JAK1 inhibitor that was engineered to address the hypothesis that greater JAK1 selectivity over other JAK family members will translate into a more favorable benefit:risk profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30886973",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib is a JAK inhibitor engineered to be selective for JAK1, and has recently been approved for use in patients with moderate-to-severe RA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32530345",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e. Upadacitinib selectively targets JAK1 dependent disease drivers such as IL-6 and IFN\u03b3, while reducing effects on reticulocytes and natural killer (NK) cells, which potentially contributed to the tolerability issues of tofacitinib.Me",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30886973",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "mia. Upadacitinib (ABT-494) is a selective JAK1 inhibitor that was engineered to address the hypothesis that greater JAK1 selectivity over other JAK family members will translate into a more favorable benefit:risk profil",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30886973",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tructure-based hypotheses were used to design the JAK1 selective inhibitor upadacitinib. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30886973",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We evaluated the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, in a randomized trial of patients with Crohn's disease (CD).M",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32044319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "sk profile. Upadacitinib selectively targets JAK1 dependent disease drivers such as IL-6 and IFN\u03b3, while reducing effects on reticulocytes and natural killer (NK) cells, which potentially contributed to the tolerability issues of tofacitinib.Methods: Structure-based hypotheses were used to design the JAK1 selective in",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30886973",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIMS: Upadacitinib (ABT-494) is a selective Janus kinase 1 inhibitor being developed for treatment of auto-immune inflammatory diso",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28503781",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor being developed for treatment of rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31448433",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "o physiological consequences. Upadacitinib is ~\u200960 fold selective for JAK1 over JAK2, and\u2009>\u2009100 fold selective",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30886973",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31448433",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here, we demonstrated that Upadacitinib, a JAK-1 inhibitor, inhibited the proliferation of cytokine-dependent ATL cell lines and the expression of p-STAT5.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33129109",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32776305",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Upadacitinib and abrocitinib are oral small molecules that inhibit the JAK/STAT pathway by selectively blocking JAK1. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32776305",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several more selective JAK-1 inhibitors, including filgotinib and upadacitinib, have also shown positive results in phase II studies and are currently enrolling in phase III development programs. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31317509",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emerging data with selective JAK1 inhibitors upadacitinib and filgotinib looks very promising",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31401212",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1-selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis (RA) who have experienced an inadequate response to methotrexate (MTX).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31287230",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29908670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29908669",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib selectively inhibits Janus Kinase 1 (JAK1) which could potentially reduce JAK2 and JAK3-related side effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30394138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib is a selective Janus Kinase 1 inhibitor which is being developed for the treatment of several inflammatory diseases including rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31654328",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib is a novel selective Janus kinase 1 inhibitor developed for treatment of rheumatoid arthritis and other autoimmune diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30633369",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upadacitinib is a selective Janus kinase 1 inhibitor being developed for the treatment of several inflammatory autoimmune diseases, including rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30973649",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Upadacitinib, an oral Janus kinase (JAK)1-selective inhibitor, showed efficacy in combination with stable background conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoid arthritis who had an inadequate response to DMARDs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31130260",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This phase 1 study characterized the effect of multiple doses of upadacitinib, an oral Janus kinase 1 selective inhibitor, on the pharmacokinetics of the cytochrome P450 (CYP) 2B6 substrate bupropion. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648334",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To date, three JAK inhibitors have been tested in patients with moderate-to-severe CD: tofacitinib (pan-JAK inhibitor), filgotinib (JAK1 inhibitor) and upadacitinib (JAK1 inhibitor).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31327403",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Janus kinase 1"
}